Business
Starpharma hunts for cash as it speeds up COVID nasal spray treatment – Sydney Morning Herald
The Melbourne biotech is in a trading halt as it launches a placement for a COVID treatment it hopes to be ready by next year.
Starpharma shares have been on a tear over the past month since the business started to update the market on progress about the nasal spray. Shares have jumped from $1.41 to $1.60 over the past month.
The nasal spray repurposes Starpharma’s antiviral product SPL7013, which is already used in its sexual health products including condoms. The company hopes the compound will bind to the SARS-COV-2 spike protein and block the virus from attaching to cells.
Earlier this month the company released d…
-
Noosa News14 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate
-
Noosa News11 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
Noosa News19 hours agoManjimup engineer turns previously wasted avocados into liquid gold
-
Noosa News13 hours agoPeter Dutton insists there’s enough water for his seven nuclear plants, contradicting shadow frontbencher